Co-Authors
This is a "connection" page, showing publications co-authored by JOSEPH KHOURY and MICHAEL ANDREEFF.
Connection Strength
0.645
-
Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice. Cell Rep Med. 2024 May 21; 5(5):101558.
Score: 0.240
-
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer J. 2018 10 19; 8(11):98.
Score: 0.163
-
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
Score: 0.056
-
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
Score: 0.052
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.048
-
TAM kinases as regulators of cell death. Biochim Biophys Acta Mol Cell Res. 2021 05; 1868(6):118992.
Score: 0.048
-
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. Haematologica. 2017 12; 102(12):2048-2057.
Score: 0.038